基于液相色谱法的洛匹那韦/利托那韦血药浓度分析研究进展

洛匹那韦/利托那韦是《新型冠状病毒感染的肺炎诊疗方案》的推荐药物。洛匹那韦/利托那韦作为特殊情况下治疗COVID-19的药物，其相关的有效性和安全性数据尚未确立，有必要开展治疗药物监测（TDM），以确保在获得良好疗效的同时避免或减轻毒副反应，并为药物毒副作用的诊断和处理提供有价值的实验室依据，将临床用药从经验模式提高到比较科学的水平。本文综述了近年来洛匹那韦/利托那韦基于液相色谱法的血药浓度测定方法研究进展，包括高效液相色谱法、液相色谱-质谱联用法、超高效液相色谱法等，以及相应的样品前处理方法，为本次COVID-19治疗药物的TDM工作提供参考。

Progress on blood concentration analysis of lopinavir/litonavir based on liquid chromatography

Lopinavir/ritonavir is a recommended drug for the "Pneumonia Diagnosis and Treatment Program for Novel Coronavirus Infections".As a drug for the treatment of COVID-19 under special circumstances,the relevant efficacy and safety data of lopinavir/ritonavir have not been established,and it is necessary to carry out therapeutic drug monitoring(TDM)to ensure that toxicity is avoided/alleviated while obtaining good efficacy,provide valuable laboratory basis for the diagnosis and treatment of toxic side effects of drugs,and improve clinical medication from empirical mode to a more scientific level.The article reviews the research progress in the determination of lopinavir/ritonavir plasma concentration based on liquid chromatography in recent years,including high performance liquid chromatography,liquid chromatography-mass spectrometry,ultra-high performance liquid chromatography,etc.,as well as the corresponding sample pretreatment methods,providing a reference for the TDM work of this COVID-19 therapeutic drug.